Under typical circumstances, this fund dedicates a minimum of 80% of its holdings to the securities that make up its benchmark index, or to other investments possessing comparable financial traits. The underlying index focuses on companies at the forefront of innovation and practical application of messenger RNA (mRNA) technology. These businesses are publicly traded on exchanges in the United States, Canada, and across Europe. It is important to note that this fund operates as a non-diversified investment.